Ranolazine injection into coronary or femoral arteries exerts marked, transient regional vasodilation without systemic hypotension in an intact porcine model

Circulation: Cardiovascular Interventions

Volumn 4, Issue 5, 2011, Pages 481-487

  Nieminen, Tuomo ^a,b,c,d   Tavares, Caio A M ^a,e   Pegler, José R M ^a,e   Belardinelli, Luiz ^f   Verrier, Richard L ^a,b  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^d PÄIJÄT HÄME CENTRAL HOSPITAL   (Finland)

^e UNIVERSITY OF SÃO PAULO   (Brazil)

^f Gilead Palo Alto Inc   (United States)

Author keywords

Percutaneous coronary intervention; Percutaneous peripheral intervention; Potassium; Sodium; Vasodilation; Vasospasm

Indexed keywords

GLYCERYL TRINITRATE; PRAZOSIN; RANOLAZINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY; CORONARY ARTERY BLOOD FLOW; CORONARY ARTERY DILATATION; DOSE RESPONSE; DRUG ACTIVITY; DRUG BLOOD LEVEL; FEMORAL ARTERY; HEART RATE; HEMODYNAMICS; HYPOTENSION; LEFT ANTERIOR DESCENDING CORONARY ARTERY; MALE; MEAN ARTERIAL PRESSURE; NONHUMAN; PRIORITY JOURNAL; SWINE; VASCULAR RESISTANCE;

ACETANILIDES; ADRENERGIC ALPHA-1 RECEPTOR AGONISTS; ANGINA PECTORIS; ANIMALS; BLOOD PRESSURE; CORONARY VESSELS; ENDOTHELIUM, VASCULAR; FEMORAL ARTERY; HUMANS; MODELS, ANIMAL; NITROGLYCERIN; PIPERAZINES; PRAZOSIN; RECEPTORS, ADRENERGIC, ALPHA-1; REGIONAL BLOOD FLOW; SWINE; VASCULAR RESISTANCE; VASODILATION;

EID: 82955173063     PISSN: 19417640     EISSN: 19417632     Source Type: Journal    
DOI: 10.1161/CIRCINTERVENTIONS.111.962852     Document Type: Article

References (24)

1. Belardinelli L, Shryock JC, Fraser H. Inhibition of the late sodium current as a potential cardioprotective principle: effects of the late sodium current inhibitor ranolazine. Heart. 2006;92(Suppl 4):iv6 - iv14. (Pubitemid 43974036)
2. Reffelmann T, Kloner RA. Ranolazine: an anti-anginal drug with further therapeutic potential. Expert Rev Cardiovasc Ther. 2010;8:319-329.
3. Morrow DA, Scirica BM, Karwatowska-Prokopczuk E, Murphy SA, Budaj A, Varshavsky S, Wolff AA, Skene A, McCabe CH, Braunwald E, for the MERLIN-TIMI 36 Trial Investigators. Effects of ranolazine on recurrent cardiovascular events in patients with non-ST-elevation acute coronary syndromes: the MERLIN-TIMI 36 randomized trial. JAMA. 2007;297:1775-1783. (Pubitemid 46658646)
4. Antzelevitch C, Belardinelli L, Zygmunt AC, Burashnikov A, Di Diego JM, Fish JM, Cordeiro JM, Thomas G. Electrophysiological effects of ranolazine, a novel antianginal agent with antiarrhythmic properties. Circulation. 2004;110:904-910. (Pubitemid 39136212)
5. Scirica BM, Morrow DA, Hod H, Murphy SA, Belardinelli L, Hedgepeth CM, Molhoek P, Verheugt FWA, Gersh BJ, McCabe CH, Braunwald E. Effect of ranolazine, an antianginal agent with novel electrophysiological properties, on the incidence of arrhythmias in patients with non ST-segment elevation acute coronary syndrome: Results from the Metabolic Efficiency with Ranolazine for Less Ischemia in Non-ST-elevation Acute Coronary Syndrome Thrombolysis in Myocardial Infarction 36 (MERLIN-TIMI 36) randomized controlled trial. Circulation. 2007;116: 1647-1652. (Pubitemid 47537839)
6. Murdock DK, Kersten M, Kaliebe J, Larrain G. The use of oral ranolazine to convert new or paroxysmal atrial fibrillation: a review of experience with implications for possible "pill in the pocket" approach to atrial fibrillation. Ind Pacing Electrophysiol J. 2009;9:260-267.
7. Kumar K, Nearing BD, Carvas M, Nascimento BCG, Acar M, Belardinelli L, Verrier RL. Ranolazine exerts potent effects on atrial electrical properties and abbreviates atrial fibrillation duration in the intact porcine heart. J Cardiovasc Electrophysiol. 2009;20:796-802.
8. Kumar K, Nearing BD, Bartoli CR, Kwaku KF, Belardinelli L, Verrier RL. Effect of ranolazine on ventricular vulnerability and defibrillation threshold in the intact porcine heart. J Cardiovasc Electrophysiol. 2008; 19:1073-1079.
9. 1-adrenoceptors in rat left ventricle by ischaemia and acyl carnitines: Protection by ranolazine. J Cardiovasc Pharmacol. 1993; 21:869-873. (Pubitemid 23160673)
10. Scirica BM, Braunwald E, Belardinelli L, Hedgepeth CM, Spinar J, Wang W, Qin J, Karwatowska-Prokopczuk E, Verheugt FWA, Morrow DA. Relationship between nonsustained ventricular tachycardia after non-STelevation acute coronary syndrome and sudden cardiac death: observations from the Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST-Elevation Acute Coronary Syndrome Thrombolysis in Myocardial Infarction 36 (MERLIN-TIMI 36) randomized controlled trial. Circulation. 2010;122:455-462.
11. Nieminen T, Nanbu DY, Datti IP, Vaz GR, Tavares CAM, Pegler JRM, Nearing BD, Belardinelli L, Verrier RL. Antifibrillatory effect of ranolazine during severe coronary stenosis in the intact porcine model. Heart Rhythm. 2011;8:608-614.
12. Hagestad EL, Verrier RL. Delayed myocardial ischemia following the cessation of sympathetic stimulation. Am Heart J. 1988;115:45-53. (Pubitemid 18032699)
13. Coppola J, Patel T, Kwan T, Sanghvi K, Srivastava S, Shah S, Staniloae C. Nitroglycerin, nitroprusside, or both, in preventing radial artery spasm during transradial artery catheterization. J Invasive Cardiol. 2006;18: 155-158. (Pubitemid 44576088)
14. Ma A, Garland WT, Smith WB, Skettino S, Navarro MT, Chan AQ, Anderson BE, John P, Cooke JP. A pilot study of ranolazine in patients with intermittent claudication. Int Angiol. 2006;25:361-369. (Pubitemid 46350993)
15. Zhao G, Walsh E, Shryock J, Messina E, Wu Y, Zeng D, Xu X, Ochoa M, Baker S, Hintze T, Belardinelli L. Anti-adrenergic and hemodynamic effects of ranolazine in conscious dogs. J Cardiovasc Pharmacol. 2011; 57:639-647.
16. Nearing BD, Hutter JJ, Verrier RL. Potent antifibrillatory effect of combined blockade of calcium channels and 5-HT2 receptors with nexopamil during myocardial ischemia and reperfusion in canines: comparison to diltiazem. J Cardiovasc Pharmacol. 1996;27:777-787. (Pubitemid 26171689)
17. Konidala S, Gutterman DD. Coronary vasospasm and the regulation of coronary blood flow. Prog Cardiovasc Dis. 2004;46:349-373. (Pubitemid 38201296)
18. Harrison DG, Bates JN. The nitrovasodilators: new ideas about old drugs. Circulation. 1993;87:1461-1467. (Pubitemid 23133088)
19. Vatner SF, Pagani M, Manders WT, Pasipoularides AD. Alphaadrenergic vasoconstriction and nitroglycerin vasodilation of large coronary arteries in the conscious dog. J Clin Invest. 1980;65:5-14. (Pubitemid 10214326)
20. Wang WQ, Robertson C, Dhalla AK, Belardinelli L. Antitorsadogenic effects of ({±})-N-(2,6-dimethyl-phenyl)-(4[2-hydroxy-3-(2-methoxyphenoxy) propyl]-1-piperazine (ranolazine) in anesthetized rabbits. J Pharmacol Exp Ther. 2008;325:875-881. (Pubitemid 351724316)
21. Attaran S, John L, El-Gamel A. Clinical and potential use of pharmacological agents to reduce radial artery spasm in coronary artery surgery. Ann Thorac Surg. 2008;85:1483-1489. (Pubitemid 351384795)
22. Cox RH. Influence of chloralose anesthesia on cardiovascular function in trained dogs. Am J Physiol. 1972;223:660-667.
23. Verrier RL, Hagestad EL, Lown B. Delayed myocardial ischemia induced by anger. Circulation. 1987;75:249-254. (Pubitemid 17234565)
24. Papageorgiou P, Hagestad EL, Verrier RL. Coronary distending pressure and delayed myocardial ischemia. Am Heart J. 1988;116:59-66.